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A recombinant baculovirus harboring the hemagglutinin (HA) gene of African swine fever virus, with homology to the T-
lymphocyte surface antigen CD2, was constructed. The efficient expression of the HA gene was determined by immunofluo-
rescence and Western blot studies on insect cells infected with the recombinant baculovirus. The baculovirus-expressed
HA showed hemadsorption and erythrocyte-agglutinating activities characteristic of the CD2 homolog protein induced by
the virus in infected macrophages. Pigs immunized with the recombinant HA developed hemagglutination-inhibition and
temporary infection-inhibition antibodies that recognize a 75-kDa structural protein and were protected against lethal infec-
tion. q 1996 Academic Press, Inc.
African swine fever virus (ASFV), the causative agent of Recently the complete nucleotide sequence of the
ASFV genome (11, 12) has been reported. Database com-African swine fever, is an icosahedral cytoplasmic deoxi-
virus that infects porcine species. The infection of domestic parisons have provided clues about genes that could
modulate virus–host interactions. One of them is a genepigs with virulent ASFV strains leads to a highly lethal dis-
ease. Pigs surviving infection with attenuated variants of with sequence similarities to the adhesion receptor of T
cells, CD2. This protein is directly involved in the hem-ASFV develop resistance to infection with homologous viru-
lent viruses (1, 2). Sera from these pigs were capable of adsorption phenomenon induced by the infection of sus-
ceptible cells with the ASFV (13, 14). DNA amplificationinhibiting the virus replication in pig buffy coat cultures (3–
5). Furthermore, in passive transfer experiments in swine, of the CD2-like gene from the Spanish attenuated isolate
E75CV1 was carried out by PCR using AmpliTaq DNAthese anti-ASFV antibodies have been shown to play a role
in protective immunity to a homologous virulent ASFV (6). polymerase (Perkin–Elmer Cetus) with the following
primers: (i) 5*-GCGCGGATCCATGATAATAATAGTTATTThe proposed humoral immune mechanisms responsible
for this protection are not conclusive and the identities of (5* primer), which includes the recognition sequence for
viral antigens responsible of inducing the protective re- the BamHI restriction enzyme, and (ii) 5*-GCGCGAATT-
sponse are unknown (7, 8). CTTAAATAATTCTATCTAC (3* primer), which contains
One of the most interesting characteristics of ASFV the recognition sequence for the EcoRI restriction en-
infection is the induction of hemadsorption of pig erythro- zyme. The DNA template was obtained from superna-
cytes to the infected cell surface (9). We have previously tants of infected CV1 cell cultures (15). The PCR product
described a virus-induced glycoprotein in ASFV-infected was digested with EcoRI and BamHI and cloned into
cells, the hemagglutinin (HA), which produces in vitro Pak 8 transfer vector under the control of the polyhedrin
hemagglutination of pig erythrocytes in the absence of promoter of baculovirus (Clontech), which had been pre-
ASFV particles (10). In preliminary experiments pigs im- viously digested with the same enzymes. The cloned
munized with nonpurified HA showed some resistance gene was sequenced by the dideoxynucleotide chain
to the homologous virulent strains (10). However, assess- termination method with specific primers, showing 100%
ment of the relevance of the immune response to HA similarity with the gene encoded by BA71V virus pre-
glycoprotein in protection is necessary to obtain this pro- viously sequenced (12). Both viruses, E75 and BA71,
tein free of other ASFV components. Therefore, we were isolated in Spain within a few years of each other
thought to produce the HA glycoprotein of ASFV using and they are probably closely related.
the baculovirus expression system. Then, a recombinant baculovirus expressing the ASFV
HA was constructed. Briefly, Sf cells were transfected
with a mixture of the transfer recombinant vector1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 34-1- 620 22 47. (pak8HA) and the purified noninfectious BacPAK6 DNA,
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induced by HABv in infected cells, but not in the wild-
type baculovirus-infected cells.
To confirm that the ASFV CD2-like protein, responsible
for hemadsorption, and the ASFV HA glycoprotein are
the same antigen, different assays were carried out.
Hemadsorption tests were performed in monolayers of
Sf cells in 35-mm dishes. The cells were infected with
either the recombinant or wild-type baculovirus at a m.o.i.
of 0.5 and incubated at 287 for 24 hr. At this time, the
culture medium was removed and 3 ml of fresh medium
mixed with 20 ml of a 20% suspension of swine erythro-
cytes was added to each dish. Rosette formation was
scored 3 hr later. Figs. 2c and 2d show the specific
formation of rosettes in the HABv-infected Sf cells.
To analyze the hemagglutination properties of the re-
combinant HA, Sf cell monolayers were infected with
either recombinant or wild-type baculoviruses at a m.o.i.
of 1, and at different days postinfection cells were har-
vested and centrifuged. Supernatants were collected and
the sedimented cells, resuspended in 1/100 of the origi-
nal volume in hemagglutination assay buffer (0.1 M so-
dium acetate, 1 mM MnCl2 , 1 mM MgCl2 , 1 mM CaCl2 ,
FIG. 1. Identification of ASFV-induced and baculovirus-expressed HA 1 M NaCl, pH 6.8), were sonicated until cell lysis was
by Western blot. Percoll-purified ASFV proteins were reacted with anti- complete. Cell debris were eliminated by centrifugation
1207 hyperimmune ASFV serum (A) or with a pool of sera generated
at 12,000 g for 30 min. Supernatants of cultures and cellagainst the recombinant HA (D). The presence of HA (75 kDa) in the
extracts were assayed for hemagglutinating activity. Theviral particle was detected only by antibodies raised against the recom-
binant HA. Hyperimmune anti-1207 ASFV serum reacted with the HA results of these assays confirmed that the HA expressed
induced by HABv recombinant baculovirus in infected insect cells (C). by the recombinant baculovirus showed hemagglutina-
No reaction with any protein was observed by using the same serum tion activity. Comparative titration between intracellular
in wild-type baculovirus-infected cells (B).
and secreted HA showed that most of the HA produced
by the recombinant baculovirus is associated to the cel-
lular fraction (40 times more hemagglutination activityBsu36I digest, which contains the b-galactosidase gene
under the control of the polyhedrin promoter of baculovi- detected in the cellular fraction than found in the super-
natant). The comparative analysis of HA production inrus (Clontech). After 4 days incubation at 287, superna-
tants were tested for plaque formation in Sf monolayers. insect cells infected at a m.o.i. of 1 with the recombinant
baculovirus at different hours postinfection showed aPlaques were recovered and then purified by three con-
secutive plaque assays in Sf cell monolayers. Selection maximum of the recombinant HA induction at 72 hr after
infection, decreasing 24 hr later (data not shown). Controlof recombinant plaques was made by color selection.
The recombinant baculovirus expressing the HA gene cultures did not show any hemagglutination activity. The
above results confirm that the hemagglutinating and(HABv) has the b-galactosidase gene replaced by the
new introduced recombinant gene and did not show ex- hemadsorbing activity shown during the ASFV infection
is due to the same protein.pression of the chromogenic marker gene.
Coomassie brilliant blue staining of HABv-infected cell In order to analyze the immunological properties of
the ASFV HA, three pigs weighing 30–40 kg were intra-extract proteins resolved in SDS–polyacrylamide gel
electrophoresis (400,000 infected cells) failed to detect musculary inoculated monthly with three doses of HABv-
infected Sf cells recovered at 72 hr postinfection, usingthe recombinant protein over the baculovirus-induced
protein background. Then, pig serum antibodies gener- Freund’s complete adjuvant for the first dose and incom-
plete for the others. Pig 1 was immunized with threeated after infection with an attenuated ASFV strain
(1207VR11), showing hemagglutination-inhibition activity doses of 107 HA units (2–4 1 108 infected cells). Pigs 2
and 3 were immunized with three doses of 5 1 106 HA(10), were used to detect specific expression of the HA by
the recombinant baculovirus. Antibodies stained HABv- units. Two control pigs (pigs 4 and 5) were inoculated
with Sf cells infected with the wild-type baculovirus (2 1infected Sf cells by immunofluorescence (data not
shown). The expression of HA by the recombinant bacu- 108 infected cells) and one pig was left as uninoculated
control (pig 6). Fifteen days after last inoculation, the pigslovirus was also examined by Western blot analysis of
infected cell extracts (Fig. 1). The anti-ASFV serum de- were bled for serum.
All immunized pigs with the recombinant baculovirustected a protein with a molecular weight of about 75 kDa
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FIG. 2. Distribution of HA in ASFV-infected cells and hemadsorption properties of the recombinant ASFV HA. To the left, antibody immunofluores-
cence of uninfected (a) and ASFV-infected Vero cells (b) at 12 hr after infection obtained with serum against the baculovirus-expressed HA (serum
from pig 1) is shown. To the right, hemadsorption in insect cells infected with the wild-type (c) or recombinant HA Bv baculovirus (d) is shown.
Swine erythrocytes were added at 24 hr after infection. Specific formations of rosettes are indicated by arrows.
developed specific antibodies against the HA as demon- 18). The low amounts of this protein in the particle, as
well as the absence or low quantity of specific antibodiesstrated by immunofluorescence experiments. Sera from
immunized pigs stained by immunofluorescence perme- against HA in most sera from ASFV-infected pigs could
explain the difficulties in the detection of this antigen inabilized Vero cells infected with the ASFV isolate
1207VR11. As shown in Figs. 2a and 2b, most of the HA the viral particle by different authors. This is exemplified
by the serum anti-1207VR11 virus, which showed hemag-detected is located at 12 hr p.i. in the cytoplasm of the
infected cells, giving a characteristic corpuscular immu- glutination-inhibition antibodies but did not detect the
HA in the viral particle, while this serum detected thenofluorescence, corresponding to the viral factories
where viral morphogenesis takes place. Interestingly, in recombinant HA overexpressed in insect cells (Fig. 1).
However, after hyperimmunization with the recombinanta time course experiment of immunofluorescence, the
HA was first detected at 12 hr after infection, simultane- HA, pigs developed enough antibodies to recognize the
HA in the viral particle in a Western blot (Fig. 1). Theseously with the first images of hemadsorption of pig eryth-
rocytes shown in parallel cultures (data not shown). data indicate that the HA protein is a minority component
of the viral particle that is detectable only by using seraTo explore the possibility that the ASFV HA was a
structural protein, extracellular BA71V ASFV particles with a high antibody titer against this protein.
The biological relevance of this finding could be ofwere purified from infected Vero cell supernatants by
Percoll equilibrium centrifugation as described else- importance in the transportation of the virus associated
to the erythrocytes (more than 90%) during in vivo infec-where (16). Then, the purified virus was analyzed by
Western blot using the anti-HA antibodies generated in tion (19, 20, 21). Electron microscope studies (22) indi-
cated that after attachment, the virion does not penetratethe immunized pigs (a pool of the three sera from pigs
1, 2, and 3). Antibodies from pigs reacted with purified the erythrocyte, but remains connected to the outside
surface via a tunnel. The HA could mediate this attach-extracellular particles, recognizing a viral protein of 75
kDa (Fig. 1), with the same electrophoretic mobility as ment, and in this manner, virions could evade the im-
mune system, explaining the long viremia periods shownthat previously described for the recombinant HA. The
presence of glycoproteins in the ASFV particle has been in survival pigs after infection with ASFV.
Anti-hemagglutinating antibody titers and the infection-discussed by several authors with different results (17,
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hibiting the cytopathic effect produced by the virus in
vitro, as previously described for sera from convalescent
pigs (3). However, all pigs immunized with the recombi-
nant HA developed the same titers of anti-hemagglutinin
antibodies. In spite of the fact that antibodies that inhibit
infection could play an important role in protection, pigs
2 and 3 in absence of these kinds of antibodies resist
the challenge exposure to a virus that kills 100% of inocu-
lated pigs. This seems to indicate that other antibody-
mediated mechanisms may contribute to the resistance
against the disease and HA seems to be the target of
these partially protective antibodies.
It has been reported that in ASFV infection, after vire-
FIG. 3. Viremia titers at different days postinfection of pigs 1 (l), 2 mia, survival pigs develop antibodies capable of inhib-(m), and 3 (j), immunized with the recombinant baculovirus expressing
iting the infection of the homologous virus in vitro (3). Asthe ASFV HA; of control pigs 4 (s) and 5 (n), inoculated with wild-type
we expected, pigs 2 and 3 at Postinfection Day 60baculovirus; and of the unimmunized control pig 6 (h).
showed, in a 5-day assay, infection-inhibition indexes of
2.66, while the infection-inhibition index from pig 1 (in
which viremia was not detectable) remained constant atinhibition index of immune sera were measured as de-
scribed (10). Hemagglutination-inhibition assays were the same days (1.16).
The data presented here clearly demonstrate that thecarried out with 8 HA units from both recombinants or
infected Vero cells obtained HA (infected with 1207VR11 hemagglutinin of ASFV is expressed functionally in a ba-
culovirus system. On the other hand, to our knowledge,virus strain). Maximum titers of 1/80 for both antigens
were obtained from monospecific sera obtained from this is the first report of protection against ASFV by using
a recombinant virus protein. This protection was similarpigs immunized with the recombinant protein. These re-
sults suggest that both antigens were functionally simi- to that obtained in passive antibody transfer experiments
using immunoglobulins purified from convalescent pigslar. Interestingly, only pig 1 inoculated with more HA
doses showed a temporary (5 days) infection-inhibition (6). The different immune response observed between
pig 1, immunized with highest doses of antigen, and pigsindex of 1.67 (titer of ASFV grown in presence of preim-
mune serum minus titer of ASFV grown in presence of 2 and 3 suggests that protection could be conferred in
a dose-dependent response to HA. Unfortunately, theimmune serum), determined by cytopathic effect in pig
buffy coat cultures. These results seem to indicate that ASFV HA is not very antigenic (10), and it will probably be
necessary to inoculate higher doses of the recombinantin the ASFV HA the epitopes responsible for inducing
infection inhibition and hemagglutination inhibition could protein to confer better protection against ASFV infection
or improve the antigenic presentation of this antigen tobe different.
To explore the possibility of protective immunity to the immune system. Experiments in this direction are
being pursued.ASFV conferred by the HA, all immunized and control
pigs were challenged intramusculary with 4 1 102 tissue
culture infectious dose 50 (TCID50 ) of the virulent strain ACKNOWLEDGMENTS
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